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Abstract 
Introduction: The free androgen index (FAI) values differ among patients with polycystic ovarian syndrome; however, the differences 
are not fully understood or known.
The aim of the study was to evaluate FAI in women with polycystic ovary syndrome (PCOS) in regard to the phenotype of the PCOS 
and insulin resistance status.
Material and methods: Anthropometric, hormonal, and biochemical parameters were assessed in 312 recruited women with PCOS. The 
FAI values were calculated in the reproductive and metabolic phenotypes of PCOS in groups of insulin resistance status based on the 
homeostasis model assessment-insulin resistance (HOMA-IR) > 2.0 or fasting insulin (FI) > 10 mmol/L. To test the relationship between 
individual variables, Spearman’s correlation analysis, the Kolmogorov-Smirnov test, and Student’s t-test were used. 
Results: The correlation between FAI values and HOMA-IR and FI was 0.42 and 0.47, respectively, in PCOS patients. A two fold higher 
FAI value was observed in metabolic PCOS phenotype when compared to the reproductive one (8.51 ± 5.56 vs. 4.40 ± 2.45 for HOMA-IR 
and 8.73 ± 6.09 vs. 4.31 ± 3.39 for FI, respectively; p < 0.05).
Conclusions: PCOS patients are not a homogenous group in terms of FAI value. Patients with metabolic PCOS phenotype are characterised 
by two-fold higher FAI values compared with reproductive PCOS phenotype. Further studies on the metabolic and androgenic status of 
different types of PCOS phenotypes should be carried out. (Endokrynol Pol 2019; 70 (4): 330–335)
Key words: polycystic ovary syndrome; free androgen index; hyperandrogenism; insulin resistance
Endokrynologia Polska
DOI: 10.5603/EP.a2019.0017
Volume/Tom 70; Number/Numer 4/2019
ISSN 0423–104X
Introduction
Polycystic ovary syndrome (PCOS) is an endocrine 
disorder affecting approximately 6–13% of women of 
reproductive age [1], characterised by reproductive and 
metabolic disorders. According to the Androgen Excess 
Society (AES), the diagnosis of PCOS is based on the 
fulfilment of criteria, including clinical or biochemical 
symptoms of hyperandrogenism, and the coexistence of 
one of the two following symptoms: oligo-ovulation/an-
ovulation or polycystic ovarian picture in ultrasound 
examination [2]. In the diagnosis of PCOS it is also 
necessary to exclude other causes of hyperandrogen-
ism, such as congenital adrenal hyperplasia, Cushing’s 
syndrome, hypothyroidism, acromegaly, or hyperpro-
lactinaemia [3]. 
PCOS is not a homogenic group of patients. There 
are several proposed phenotypes of the disorder. 
According to AES, three clinical PCOS phenotypes have 
been distinguished depending on the occurrence of 
polycystic ovaries, hyperandrogenisms, and oligo-ovu-
lation. According to Dunaif and Diamanti-Kandarakis, 
the phenotypes are dependent on the metabolic status 
of patients, and there are reproductive and metabolic 
phenotypes [4].
The reproductive phenotype is characterised by 
hyperandrogenaemia [5], which is clinically manifested 
in 60% of patients as hirsutism and less often as acne or 
androgenic alopecia [6]. Ovarian dysfunction defined 
as oligo or anovulation may also be present. The mani-
festation of metabolic phenotype, besides hyperandro-
genaemia and ovarian dysfunction, include insulin 
resistance (IR) status [7]. Insulin resistance is defined 
by a fasting insulin concentration over 10 mU/mL and 
a HOMA-IR value (homeostasis model assessment-in-
sulin resistance) over 2 [8, 9].
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fasting glucose [mmol/L])/22.5. HOMA-IR > 2 and fasting insulin 
levels > 10 mU/mL were considered to be values corresponding 
to insulin resistance (IR) [15, 16].
The free androgen index (FAI) was determined on the basis of 
total testosterone and SHBG concentration in accordance with 
the formula: FAI = total testosterone [nmol/L]/SHBG [nmol/l]*100. 
Ultrasonography of the ovaries was performed in all patients using 
transvaginal method (USG TV) or transabdominal method (USG 
TA) in virgins, and as preferred. 
Taking into account the state of insulin sensitivity, patients partici-
pating in the study were divided into metabolic and reproductive 
phenotype according to the assumptions of Dunaif and Diamanti-
Kandarakis [4]. In the first part of the study, the metabolic and 
reproductive groups were distinguished based on the HOMA-IR 
value, with a cut-off value of 2 (Fig. 1). In the second part of the 
study, the division was made based on fasting insulin concentration 
with a cut-off value of 10 mU/mL (Fig. 2).
Subsequently, the mean FAI values for each group were calculated 
and compared between groups, and thus the average FAI value 
for the reproductive and metabolic phenotype of PCOS was de-
termined.
Physical examination
All participants of the study underwent physical examination, 
which included body mass and height measurement, on the basis 
of which the body mass index (BMI) was determined according to 
the formula: BMI = body mass [kg]/height [m]2. 
Clinical sings of hyperandrogenism were assessed using the 
Ferriman-Gallwey scale, in which a score above eight indicated 
hirsutism. 
Clinically, hyperandrogenism is assessed using the 
Ferriman-Galwey hirsutism score, while the biochemi-
cal exponent of hyperandrogenism is the elevated level 
of free serum testosterone [10]; however, due to the 
cost and difficulty of this test [11], usually the total 
testosterone concentration is determined. Based on 
total testosterone and sex hormone-binding globulin 
(SHBG), the value of the free androgen index (FAI) 
is determined, which serves as the main measure of 
androgenisation [12]. 
Tissue resistance to insulin influences the equalising 
increase in insulin production and hyperinsulinaemia, 
and this in turn stimulates the production of adrenal 
androgens [13]. In addition, increased insulin levels 
inhibit SHBG synthesis in the liver, thereby increas-
ing the concentration of free testosterone [14]. These 
mechanisms are responsible for increased intensity of 
androgenisation in women with insulin resistance, and 
thus higher FAI values.
The issue of the FAI cut-off point is not fully under-
stood and can differ in individual populations. The aim 
of the study was to estimate the mean FAI value in the 
polycystic ovarian syndrome, depending on the phe-
notype of the disease, and to determine the correlation 
between the index of free androgens and the indicators 
of the state of insulin sensitivity.
Material and methods
The study included 312 women aged 18 to 40 years, mean age 25.4 ± 
4.83 years (x ± SD), who were patients of the Clinical Department of 
Gynaecological Endocrinology and Gynaecology of the University 
Hospital in Krakow. PCOS was diagnosed using the AES criteria 
[2]. Oligo-ovulation was defined as menstrual periods that occur 
at intervals over 35 days, and anovulation as a complete absence of 
menstruation. Clinical hyperandrogenism was defined by the oc-
currence of acne or hirsutism, and biochemical hyperandrogenism 
by total serum testosterone levels above 1.67 nmol/L and elevated 
DHEAS concentration (depending on age: values above 5.42–11.1 
µmol/l). The ovaries in the ultrasound picture were considered to 
be polycystic in the case of ovarian volume above 10 ml and the 
presence of at least 12 follicles 2–9 mm in diameter [2]. Exclusion 
criteria included: use of oral contraception in the last two months, 
congenital adrenal hyperplasia, Cushing’s syndrome, uncontrolled 
hypothyroidism, acromegaly, hyperprolactinaemia, pregnancy, 
and lactation. Approval of the Ethics Committee of Jagiellonian 
University Medical College in Krakow was obtained. All patients 
involved in the study gave signed, informed consent (Resolution 
No. KBET/167/B/2013). 
The measurement of body mass [kg] and height [cm] was per-
formed, the body mass index (BMI [kg/m2]) was calculated. Total tes-
tosterone [nmol/L], sex hormone binding globulin (SHBG [nmol/L]), 
dehydroepiandrosterone sulphate (DHEA-S [µmol/l]), prolactin in 
the diurnal profile (PRL [uIU/mL]), daily cortisol rhythm [nmol/L], 
17-OH-progesterone [ng/mL], luteinising hormone [LH IU/L], 
follicle-stimulating hormone (FSH [IU/L]), oestradiol [pmol/L], 
and thyrotropin hormone (TSH uIU/mL) in serum were measured. 
Glucose [mmol/L] and insulin levels [mU/mL] were measured while 
fasting and 60 and 120 minutes after 75 g of oral glucose loading. To 
determine insulin sensitivity, the HOMA-IR value was determined 
according to the formula: HOMA-IR = (fasting insulin [mU/mL] x 
Study population
PCOS patients
(n = 312)
Group 1A
Reproductive PCOS phenotype
(n = 155)
Hyperandrogenaemia
HOMA-IR < 2
Group 2A
Metabolic PCOS phenotype
(n = 157)
Hyperandrogenaemia
HOMA-IR > 2
Figure 1. Division into two groups based on HOMA-IR value. 
HOMA-IR — homeostasis model assessment-insulin resistance; 
PCOS — polycystic ovary syndrome
Study population
PCOS patients
(n = 312)
Group 1B
Reproductive PCOS phenotype
(n = 166)
Hyperandrogenaemia
Fasting insulin < 10 mU/mL
Group 2B
Metabolic PCOS phenotype
(n = 146)
Hyperandrogenaemia
Fasting insulin >10 mU/mL
Figure 2. Division into two study groups based on FI 
concentration. FI — fasting insulin; PCOS — polycystic ovary 
syndrome 
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Laboratory tests
Participants of the study had blood samples collected in the morn-
ing, after an overnight fast, between the second and the sixth day 
of the menstrual cycle (follicular phase). The basic material was pe-
ripheral blood serum, which was centrifuged and stored at between 
–20°C and –70°C depending on the method. All parameters were 
determined with electrochemiluminescence immunoassay (ECLIA) 
methods using a Roche Cobas 6000 with a Cobas e601 module 
using automated commercial immunoassays (Roche Diagnostics 
International Ltd., Switzerland). The glucose concentration was 
determined by colorimetry using the automated Cobas8000 test. 
The FAI value and HOMA-IR were calculated using the formulas 
quoted above.
Statistical analysis 
STATISTICA 13 was used to perform the statistical analysis. All 
parameters were given as mean ± standard deviation. Because 
the distribution of most variables was not normal, nonparametric 
statistics were used. Comparisons of individual variables were made 
using the Kolmogorov-Smirnov test and Student’s t-test. To test the 
relationship between individual variables, Spearman’s correlation 
analysis was used. For all analyses, the determinant of statistical 
significance was p < 0.05
Results
A total of 312 women took part in the study. The mean 
age of the respondents was 25.4 ± 4.83 years (x ± SD), 
mean BMI was 24.93 ± 6.05, mean HOMA-IR was 
2.748 ± 2.951, mean testosterone was 2.042 ± 0.966 , and 
mean FAI was 6.454 ± 5.385. In total, 157 and 146 women 
were diagnosed as metabolic phenotype according to the 
HOMA-IR > 2.0 or FI > 10 used, and 155 and 165 women 
presented with reproductive phenotype. The character-
istics of the groups are presented in Table I and II. 
In all subjects with PCOS there was a correlation be-
tween HOMA-IR and FI and testosterone (respectively, 
0.29 and 0.31) and between HOMA-IR and FI and FAI 
— 0.42 and 0.47, respectively (Fig. 3 and 4). The women 
with metabolic phenotype were heavier and had higher 
BMI compared to reproductive type irrespective of the 
insulin resistance indicator used (p = 0.00). The testos-
terone levels were higher in metabolic vs. reproductive 
Table I. Characteristic of study group — divided into two PCOS phenotypes depending on HOMA-IR
Group 1A (HA+ HOMA-IR < 2)  
(n = 155)
Group 2A (HA+ HOMA-IR > 2)  
(n = 157)
p-value
Age [yrs] 25.26923 ± 4.80 25.35 ± 5.95 0.89
Height [cm] 166.2961 ± 5.485488 166.41 ± 6.44 0.87
Weight [kg] 61.18 ± 11.22 76.01 ± 18.45 0.00
BMI [kg/m2] 22.08 ± 3.86 27.35 ± 6.17 0.00
FAI 4.40 ± 2.45 8.51 ± 5.53 0.00
Testosterone [nmol/L] 1.92 ± 0.88 2.14 ± 1.01 0.043
PCOS — polycystic ovary syndrome; HA — hyperandrogenaemia; HOMA-IR — homeostasis model assessment-insulin resistance; BMI — body mass index;  
FAI — free androgen index
Table II. Characteristic of study group — divided into two PCOS phenotypes depending on fasting insulin
Group 1B (HA+ FI < 10 mU/mL)  
(n = 166)
Group 2B (HA+ FI > 10 mU/mL)  
(n = 146)
p-value
Age [yrs] 25.28±4.78 25.35 ± 6.04 0.92
Height [cm] 166.27 ± 5.58 166.45 ± 6.39 0.79
Weight [kg] 61.35± 11.70 76.79 ± 18.24 0.00
BMI [kg/m2] 22.10 ± 3.96 27.64 ± 6.08 0.00
FAI 4.37 ± 3.39 8.73 ± 6.09 0.00
Testosterone [nmol/L] 1.93 ± 0.89 2.18 ± 1.03 0.017
PCOS — polycystic ovary syndrome; HA — hyperandrogenaemia; FI — fasting insulin; BMI — body mass index; FAI — free androgen index
y = 0.3187x + 2.6485
R² = 0.2204
F
A
I
Fasting insulin [uU/mL]
30
25
20
15
10
5
0
0                10                20                30               40                50               60
Figure 3. Correlation between FAI and FI [mmol/L] concentration 
in all PCOS patients (n = 355). FAI — free androgen index; 
FI — fasting insulin; PCOS — polycystic ovary syndrome
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phenotype (2.14 ± 1.01 nmol/L vs. 1.92 ± 0.88 nmol/L 
for HOMA-IR, and 2.18 ± 1.03 nmol/L vs. 1.93 ± 0.89 
nmol/L for FI). The FAI value was higher in metabolic 
vs. reproductive phenotype (8.51 ± 5.53 vs. 4.40 ± 2.45 
for HOMA-IR, and 8.73 ± 6.09 vs. 4.37 ± 3.39 for FI) 
(Tab. I and II). 
Discussion
In the study, the mean FAI value was estimated in two 
phenotypes of polycystic ovary syndrome, defined 
by Dunaif and Diamanti-Kandarakis [4], and the re-
lationship between the state of insulin sensitivity and 
androgen concentration was determined. The study 
shows the relationship between FAI values and insulin 
resistance status in all PCOS patients; however, the 
index of free androgens is twofold higher in the meta-
bolic PCOS phenotype as compared to the reproductive 
phenotype. Similarly, in this phenotype the level of total 
testosterone is significantly higher. 
The obtained results are consistent with many other 
studies carried out in this area [17–21], but they are in 
contrast to the results obtained by Ganie et al. [22]. The 
reason for the differences may be the use of only one of 
the androgenisation exponents (e.g. androstenedione 
or total testosterone), which, in the case of PCOS, may 
cause underestimation [23]. Due to the fact that the 
free androgen index was considered the most objec-
tive assessment of androgenisation [24], it was used in 
our study.
In our study we also observed a correlation between 
insulin concentrations and HOMA-IR values with 
FAI, which is consistent with the results obtained by 
Kissebah et al. [25] and Burghen et al. [26]. There was 
also a correlation between total testosterone level and 
insulin concentration and HOMA-IR values, which 
is consistent with the Burghen study [26]. Significant 
positive correlation between HOMA-IR as well as BMI 
and FAI and testosterone level in PCOS patients was 
obtained also in the study conducted by Dickerson et 
al. [27]. However, some studies showed different results 
presenting negative correlation between testosterone 
level and insulin and HOMA-IR [28].
The mean FAI value, calculated in all PCOS patients, 
was 4.39. For the metabolic phenotype, the average FAI 
was much higher, at 8.6. The above results differ from 
the values of the mean FAI values obtained in other 
studies. Nadajara et al. [29], in a study conducted in 
a Malaysian population of women with PCOS, found 
a mean FAI value of 9.2. A study among Chinese 
women showed a mean FAI > 6.1 [31], while a Samoan 
population survey showed a higher value, i.e. 8.5 [30]. 
However, a European population study, conducted by 
Hahn et al., showed as FAI of 4.97 as the mean value in 
PCOS patients, which is closest to the value observed 
in our study [32]. The reason for the differences in 
FAI values may be the ethnic diversity of the stud-
ied populations, but also the different measurement 
methods used. 
The androgen level in PCOS patients was analysed 
also in the studies, which divided patients according 
to their metabolic status. Brand et al. conducted a me-
ta-analysis that showed the association between higher 
total and free testosterone levels and a prevalence of 
metabolic status in PCOS patients [33]. Positive correla-
tion between androgen levels and metabolic status was 
observed also in other studies [34]. However, in the 
study conducted by Albu et al. the results were differ-
ent — there were no significant differences between the 
estimated values  of total testosterone in PCOS patients 
without and with metabolic syndrome [35], while the 
mean FAI value for PCOS patients without metabolic 
syndrome was 5.64 and in patients with co-occurring 
metabolic syndrome it was 10.26. The reason for that 
may be the division into phenotypes without using 
HOMA-IR or FI.
Some strengths and limitations of our study need to 
be discussed. This is one of the first studies investigat-
ing the androgen status in relation to phenotypes of 
PCOS in a Polish population. However, it was carried 
out only in one research centre, and thus concerned 
women living in a particular region of Poland. Also, 
the definition of insulin resistance was based on fast-
ing insulin level and HOMA-IR values, while the “gold 
standard” remains the value of the metabolic clamp 
[36]. The study with the use of the metabolic clamp 
was performed on the subgroup of patients; therefore, 
it was not presented in the above manuscript. The 
cut-off values of HOMA-IR and fasting insulin level 
are variously defined by individual researchers; how-
ever, in our study the values used were close to those 
Figure 4. Correlation between FAI and HOMA-IR in all PCOS 
patients (n = 355). FAI — free androgen index; HOMA-IR 
— homeostasis model assessment-insulin resistance; PCOS — poly-
cystic ovary syndrome
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y = 1.0468x + 3.5706
R² = 0.1733
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found for the Polish population [10]. Despite the above 
limitations, the study allowed us to estimate the mean 
FAI value in particular PCOS phenotypes and thus to 
show the dependence between insulin resistance and 
the intensity of androgenisation. 
Conclusions
Patients with metabolic PCOS phenotype are charac-
terised by two-fold higher FAI values compared with 
reproductive PCOS phenotype, suggesting that PCOS 
patients are not a homogenous group in relation to an-
drogen excess. Further studies investigating the relation 
between the metabolic and androgenisation status of 
women with PCOS should be carried out. 
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